9 February 2018

Contents

Editorial

• 09 February 2018: vol 19 no 3

Antiretrovirals

• Bictegravir approved in the US in new integrase-inhibitor based FDC (Biktarvy)

• US approve a lower-dose efavirenz (400 mg) based generic FDC (Simfi Lo)

• ViiV announces phase 3 study switching to dolutegravir/3TC dual therapy from TAF-containing ART

• US darunavir label updated: drug interactions and pregnancy

Treatment access

• 75% of WHO essential medicines could be cheaper: UK and South Africa both overpay

• London clinic to prescribe generic PrEP privately at £55 for 30 tablets

Pregnancy

• New HIV pregnancy study uses latest ART: IMPAACT 2010 study (VESTED) includes dolutegravir and tenofovir alafenamide (TAF)

• Association between timing of maternal ART and risk of infants born small for gestational age in Dutch ATHENA cohort

Guidelines

• BHIVA standards of HIV care (2018): online for comment

• UK HIV pregnancy guidelines (2018): online for comment

On the web

• HIV conversations in the UK

• Women in Science: IAS feature

• Yale CRIT conference: blogs on the threats from changes to drug regulation in the US and Europe

PDFs

• 09 February 2018: vol 19 no 3